Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 6/2/26 | Bristol Myers Squibb (BMY) | Iza-bren for Triple-Negative Breast Cancer (TNBC) | Subscribers Only | Subscribers Only | Subscribers Only |
| 6/2/26 | AstraZeneca (AZN) | camizestrant for Breast Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 6/2/26 | AstraZeneca (AZN) | camizestrant for HR+/HER2- Breast Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 6/1/26 | AstraZeneca (AZN) | Imfinzi for Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) | Subscribers Only | Subscribers Only | Subscribers Only |
| 6/1/26 | AstraZeneca (AZN) | Imjudo for Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/26/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 09/08/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 09/17/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |